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Study	  highlights:	  	  
• We	   identified	   six	   cytokines	   (IL15,	   LTA,	   CCL7,	   CCL8,	   CCL25,	   CCL27)	   with	   lower	  
expression	   levels	   in	   skeletal	   muscles	   of	   symptomatic	   patients	   with	   OPMD,	   but	  
unchanged	  in	  pre-­‐symptomatic	  expPABPN1	  carriers.	  	  
• Five	   of	   six	   OPMD-­‐dysregulated	   cytokine	   genes	   clustered	   tightly	   in	   controls.	   This	  
clustering	  was	  found	  to	  be	  disrupted	  in	  OPMD.	  	  
• Down-­‐regulated	   cytokine	   genes	   in	   OPMD	   patients	   were	   up-­‐regulated	   in	   a	   mouse	  
model	   of	   OPMD.	   	   In	   humans,	   the	   expression	   of	   these	   cytokines	   correlates	   with	  
disease	   severity	   rather	   than	   age.	   In	   OPMD	  mice,	   their	   expression	   correlated	   also	  
with	  age.	  
• The	   findings	   suggest	   that	   the	   cytokines	  with	   altered	   expression	   in	  OPMD	  patients	  
are	  putative	  biomarkers	  for	  muscle	  weakness	  in	  OPMD.	  	  




Cytokines	   are	   circulating	   immunogenic	   molecules,	   and	   their	   potential	   as	   biomarkers	   has	  
been	   exploited	   in	   the	   last	   decade.	   Cytokines	   are	   expressed	   in	   many	   tissues,	   including	  
muscles,	  but	  their	  application	  to	  monitoring	  muscle	  pathology	  in	  neuromuscular	  disorders	  is	  
sparse.	  Oculopharyngeal	  muscular	  dystrophy	   (OPMD)	   is	   a	  dominantly	   inherited,	   late-­‐onset	  
myopathy,	  caused	  by	  an	  alanine-­‐expansion	  mutation	   in	  the	  gene	  encoding	  for	  Poly(A)	  RNA	  
binding	  protein	  1	  (expPABPN1).	  Biomarkers	  for	  OPMD	  disease	  severity	  and	  progression	  are	  
not	   available.	   We	   identified	   candidate	   cytokines	   with	   altered	   expression	   levels	   in	   OPMD	  
mice	   carrying	  PABPN1	  mutations.	  Down-­‐regulation	  of	   six	   cytokines,	   IL15,	   LTA,	   CCL7,	   CCL8,	  
CC25	   and	   CCL27,	   was	   found	   in	   vastus	   lateralis	   muscle	   from	   OPMD	   patients,	   but	   not	   in	  
expPABPN1	   carriers	   at	   a	   pre-­‐symptomatic	   stage.	   In	   contrast,	   these	   cytokines	   were	   up-­‐
regulated	  in	  the	  mouse	  model	  of	  OPMD.	  These	  six	  cytokines	  formed	  a	  distinguished	  cluster,	  
which	  was	  dispersed	  in	  OPMD.	  Our	  findings	  indicate	  that	  this	  cytokine	  network	  is	  a	  potential	  
biomarker	  for	  muscle	  weakness	  in	  OPMD.	  	  
	  
	  




Ideal	   molecular	   biomarkers	   can	   quantitatively	   and	   accurately	   detect	   changes	   in	   medical	  
conditions.	  Quantitative	  biomarkers	  can	  provide	  accurate	  clinical	  assessment	  of	  pathological	  
conditions,	   moreover	   a	   patient’s	   response	   to	   therapy.	   The	   advantage	   of	   molecular	  
biomarkers	   is	   high	   sensitivity	   that	   can	   detect	   early	   stages	   of	   a	   disease,	   and	   efficacy	   of	  
therapy	   (1,	   2).	   Secreted	  molecules,	   such	   as	   cytokines	   and	  miRNA,	   have	   been	   explored	   as	  
biomarkers,	   particularly	   when	   these	   molecules	   are	   believed	   to	   be	   secreted	   from	   the	  
primarily	   affected	   tissue	   into	   the	   blood	   plasma.	   The	   advantages	   of	   cytokines	   levels	   are	  
modulated	   by	   different	   pathological	   conditions	   and	   can	   by	   robustly	   monitored	   using	  
multiplex	  quantitative	  assays,	  which	  further	  can	  be	  used	  in	  different	  prediction	  models	  like	  
risk	  assessment	  and	  toxicity	  (3).	  Changes	  in	  cytokines	  networks	  in	  blood	  have	  been	  found	  in	  
a	  wide	   range	   of	   disorders	   that	   are	   associated	  with	   the	   immune	   system,	   such	   as	   different	  
cancers,	   rheumatoid	   arthritis,	   neuroinflammatory	   CNS	   disorders,	   and	   Systemic	   Lupus	  
Erythematosus	   (1,	   4-­‐7).	   Cytokines	   as	   potential	   biomarkers	   were	   also	   reported	   in	   diverse	  
conditions	   like	   stroke,	   heart	   faliure,	  mood	   disorders	   (8,	   9)	   (9)	   (10),	   and	   in	   some	  muscular	  
dystrophies	  like	  Duchenne	  muscular	  dystrophy	  (DMD)	  (11).	  	  In	  DMD,	  elevation	  in	  circulating	  
cytokines	   is	   probably	  due	   to	   an	   increase	   in	   inflammation	   (11).	   Changes	   in	   cytokines	   levels	  
were	   also	   found	   after	   change	   in	   muscle	   exercise	   (12-­‐14)	   and	   in	   elderly	   (15,	   16).	   These	  
studies	  suggest	   that	  cytokines	   levels	  can	  monitor	  changes	   in	  muscle	   function	   in	  conditions	  
without	   inflammation.	   So	   far,	   biomarkers	   for	   rare	   neuromuscular	   disorders,	   such	   as	  
oculopharyngeal	  muscular	  dystrophy	  (OPMD),	  have	  not	  been	  identified.	  	  	  	  
OPMD	   is	   a	   dominantly	   inherited	   myopathy,	   characterized	   by	   weakness	   of	   ocular	   and	  
pharyngeal	   muscles	   typically	   starting	   from	   the	   fifth	   decade	   (17).	   OPMD	   is	   caused	   by	   an	  
alanine-­‐expansion	  mutation	  in	  the	  gene	  encoding	  for	  PABPN1	  (18).	  OPMD	  pathophysiology	  
has	   been	   studied	   with	   the	   A17.1	   mouse	   model,	   which	   was	   generated	   by	   stable	  
overexpression	   of	   the	   expanded	   PABPN1	   under	   a	   muscle-­‐specific	   promoter	   (19).	   The	  
hallmark	  of	  OPMD	  is	  formation	  of	  PABPN1	  aggregates	   in	  myonuclei	  (20),	  and	  is	  considered	  
as	  the	  histocytological	  mark	  for	  the	  disease.	  Indeed,	  animal	  models	  for	  OPMD	  were	  assessed	  
for	   aggregates	   formation	   and	   muscle	   weakness	   in	   those	   models	   were	   correlated	   with	  
aggregate	  formation	  and	  muscle	  pathology	  (19,	  21,	  22).	  Moreover,	  aggregates	  were	  used	  to	  
assess	   the	   efficiency	   of	   small	   molecules	   as	   potential	   therapies	   for	   OPMD	   (19,	   21,	   23).	  
Recently,	  we	   reported	   that	   in	   heterozygous	   carriers	   of	   expanded	   PABPN1,	   aggregates	   are	  
found	   prior	   to	   muscle	   symptoms,	   aggregates	   abundance	   in	   vastus	   lateralis	   muscle	   was	  
	  	  
similar	   to	   that	   in	   symptomatic	   OPMD	   patients	   (24).	   This	   calls	   for	   accurate	   biomarkers	   in	  
OPMD	  that	  could	  assess	  pre-­‐clinical	  signs	  of	  disease.	  	  
PABPN1	   is	   a	   regulator	   of	  mRNA	   processing	   and	   changes	   in	   PABPN1	   levels	   cause	   genome-­‐
wide	  changes	  in	  mRNA	  expression	  profiles	  (25),	  which	  we	  have	  previously	  reported	  in	  mRNA	  
levels	  of	  OPMD	  muscles	  (26,	  27).	  Amongst	  the	  dysregulated	  functional	  groups,	  we	  identified	  
the	  cytokine	  activity	  group	  to	  be	  significantly	  affected	   in	  OPMD	  and	  mice	  models	   (27).	  We	  
then	  hypothesized	  that	  changes	  in	  cytokine	  levels	  in	  affected	  OPMD	  muscles	  could	  mark	  the	  
symptomatic	  state.	  	  	  
	  
	  
	   	  
	  	  
Results	  and	  discussion	  
	  
mRNA	  expression	  profiles	  of	  the	  OPMD	  mouse	  model,	  A17.1,	  included	  up-­‐regulation	  of	  the	  
cytokine	  activity	  functional	  group	  (28).	  We	  reported	  that	  up-­‐regulation	  in	  this	  mouse	  model	  
is	   caused	   by	   alternative	   polyadenylation	   site	   usage	   in	   the	   3'-­‐UTR,	   and	   in	   this	   study	   we	  
identified	   cytokines-­‐related	   genes	   to	   be	   significantly	   affected	   (29).	   We	   studies	   cytokines	  
levels	   in	   the	   vastus	   lateralis	  muscle	   as	   limb	  girdle	  muscles	  weakness	   is	   often	  amongst	   the	  
initial	  muscle	  symptoms	  in	  our	  patients	  (24).	  mRNA	  expression	  levels	  of	  15	  cytokines-­‐related	  
genes	  were	   quantified	   using	   RT-­‐qPCR,	   initially	   in	   a	   subset	   of	   7	  OPMD	  patients	   and	   9	   age-­‐
matched	  controls	   (Supplementary	  Fig.	  1).	  A	   significant	   lower	  expression	   level	   in	  OPMD	  vs.	  
controls	  was	  found	  for	  four	  genes	  (CCL7,	  CCL8,	  CCL25,	  CCl27;	  p-­‐value	  <	  0.05),	  and	  for	  three	  
genes	   (IL-­‐15,	   IRF1,	   LTA)	   fold	   changes	   were	   in	   the	   same	   direction	   without	   statistical	  
significance	   (p-­‐value	   =	   0.06)	   (Supplementary	   Fig.	   1).	   These	   seven	   genes	   were	   further	  
analyzed	   in	   control	   N=15	   and	   OPMD	  N=16	   (Supplementary	   Table	   1).	   Lower	   expression	   of	  
CCL7,	  CCL8,	  CCL25,	  CCL27,	   IL15	  and	  LTA	  was	   found	   in	  OPMD,	  while	   the	  expression	  of	   IRF1	  
did	  not	  differ	  between	  control	  and	  OPMD	  (Fig.	  1A).	  	  
We	  then	   investigated	  whether	  a	  change	   in	  cytokines	   levels	   is	  associated	  with	  symptoms	   in	  
expPABPN1	   carriers.	   Uniquely	   to	   our	   OPMD	   dataset,	   we	   previously	   collected	   VL	   muscle	  
biopsies	   from	  younger	  OPMD	  family	  members	  without	  muscle	  symptoms.	  The	  expPABPN1	  
carriers	   were	   identified	   using	   a	   genetic	   test,	   and	   defined	   as	   pre-­‐symptomatic	   or	   OPMD	  
patients	  based	  on	   symptoms	  (24,	   26).	  Muscles	   from	  pre-­‐symptomatics	   showed	  a	  normal	  
muscle	   histology,	   however	   nuclear	   aggregates	   were	   found	   to	   the	   same	   extent	   as	   in	  
symptomatic	  patients	  (24).	   In	   contrast	   to	  OPMD	  muscles,	   the	  expression	   levels	  of	   the	   six	  
cytokines	   in	   the	  expPABPN1	  carriers	  did	  not	  differ	   significantly	   from	  age-­‐matched	  controls	  
(Fig.	   1B).	  We	   then	  assessed	  whether	   cytokines	   levels	   are	   affected	  by	   age.	  None	  of	   the	   six	  
cytokines	  were	  found	  to	  be	  age-­‐associated	  (Supplementary	  Table	  2).	  Together,	  this	  indicates	  
that	  expression	  of	  these	  six	  cytokines	  is	  primarily	  associated	  with	  symptoms	  in	  expPABPN1	  
carriers.	  	  
In	  the	  A17.1	  mouse	  model	  for	  OPMD,	  the	  expPABPN1	  gene	  is	  constitutively	  expressed	  under	  
a	  muscle	   specific	  promoter	  and	   changes	   in	  mRNA	  expression	  profiles	   are	   found	   in	  6-­‐week	  
old	   mice	   (28).	   Muscle	   weakness	   and	  muscle	   pathology	   in	   this	   mouse	  model	   is	   found	   at	  
week	  18	  and	  onwards,	  predominantly	  in	  fast	  muscles,	  such	  as	  TA	  (28).	  A	  change	  in	  the	  six	  
OPMD-­‐dysregulated	  cytokines	  was	  indeed	  found	  in	  A17.1	  TA	  muscles	  from	  6	  week-­‐old	  mice	  
(Fig.	  1C).	  However,	   in	  contrast	  to	  OPMD,	  a	  positive	  fold	  change	  was	  found	  in	  the	  A17.1	  TA	  
	  	  
muscle	   (Fig.	   1C).	  We	   found	   that	   in	   the	   A17.1	   18	   weeks	   old	   mice,	   only	   Il17,	   Ccl7	   and	   Lta	  
remained	  significantly	  elevated	  (Fig.	  1D).	  We	  then	  distinguished	  between	  the	  contribution	  of	  
age	  and	  genetics	   to	  cytokine	  expression	   levels	  using	   linear	   regression	  models	   stratified	   for	  
genetics.	  We	  found	  that	  the	  expression	  of	  Il15,	  Lta,	  Ccl25	  and	  Ccl27	  was	  significantly	  reduced	  
with	   age	   in	   A17.1	  mice	   (Supplementary	   Table	   2).	   The	   expression	   of	   Il15	   and	   Lta	  was	   also	  
reduced	  with	  age	   in	   the	  control	  mice	   (Supplementary	  Table	  2).	  This	   suggests	   that	   reduced	  
expression	  with	   age	  of	   Ccl25	   and	  Ccl27	   is	   predominantly	   affected	  by	   expPABPN1	  whereas	  
that	  of	  Il15	  and	  Lta	  is	  less	  affected	  by	  expPABPN1.	  	  
Next,	  we	   assessed	  whether	   patterns	   of	   co-­‐expression	   could	   be	   identified,	   as	   indicators	   of	  
gene	   network.	   Co-­‐expression	   between	   every	   two	   genes	   was	   assessed	   by	   Pearson	  
correlations	   (Supplementary	   Table	   3),	   and	   clustering	   of	   the	   expression	   profiles	   was	  
determined.	   Two	   separate	   groups	   were	   identified,	   using	   all	   15	   cytokine-­‐related	   genes	   in	  
control	   (Fig.	  2A).	  A	  strong	  correlation	  cluster	  encompassed	  LTA,	  CCL7,	  CCL8,	  CCL25,	  CCL27,	  
and	   PPBP,	   and	   a	  weaker	   cluster	   included	   IRF1,	   IRL1,	   CMTM4,	   SPP1	   and	   IRL2	   (Fig.	   3A	   and	  
Supplementary	  Table	  3A).	  The	  expression	  of	  the	  control	  gene,	  GUSB,	  did	  not	  have	  significant	  
correlations	   with	   any	   of	   the	   cytokine	   genes	   (Fig.	   2A).	   Remarkably,	   in	   the	   most	   highly	  
correlated	  cluster,	  five	  out	  of	  the	  six	  genes	  were	  identified	  as	  having	  a	   lower	  expression	  in	  
OPMD.	   In	   contrast	   to	   the	   pattern	   of	   association	   between	   genes	   in	   control,	   clustering	  was	  
disrupted	  in	  OPMD	  (Fig.	  3A).	  We	  then	  further	  assessed	  clustering	  of	  the	  OPMD	  dysregulated	  
cytokines	  in	  the	  extended	  dataset.	  In	  control,	  the	  LTA,	  CCL7,	  CCL8,	  CCL25,	  and	  CCL27	  cluster	  
remained	  distinguished,	  but	   in	  OPMD	  correlations	  between	  those	  genes	  were	  weaker	   (Fig.	  
2B	  and	  Supplementary	  Table	  3B).	  This	  analysis	  reveals	  that	  these	  cytokines	  co-­‐expressed	  in	  
muscles	   from	   controls	   creating	   an	   expression	   network,	   but	   this	   network	   is	   disrupted	   in	  
OPMD.	  	  
We	   also	   assessed	   co-­‐expressions	   in	   the	   A17.1	  mouse	  model.	   In	   contrast	   to	   the	   results	   in	  
humans,	   in	  control	  FVB	  mouse	  Lta,	  Ccl7,	  Ccl8,	  Ccl25,	  and	  Ccl27	  did	  not	   form	  a	  cluster	   (Fig.	  
3C).	   The	   co-­‐expression	   correlation	   pattern	   differed	   between	   FVB	   and	   A17.1,	   but	   a	  
recognized	  cluster	  was	  not	  formed,	  instead	  a	  small	  cluster	  including	  Lta,	  Ccl25	  and	  Ccl27	  was	  
found	   in	   A17.1	   (Fig.	   3C).	   This	   indicates	   that	   the	   pattern	   of	   cytokines	   co-­‐expression	   differs	  
between	  OPMD	  patients	  and	  the	  OPMD	  mouse	  model.	  	  
To	  investigate	  whether	  these	  six	  cytokines	  could	  potentially	  be	  robust	  predictive	  biomarkers	  
for	  OPMD,	  we	  applied	  a	  multivariable	  linear	  regression	  model	  adjusting	  for	  gender,	  age	  and	  
batch	   effects.	   In	   humans,	   as	   expected,	   all	   six	   cytokines	   were	   found	   to	   be	   significantly	  
associated	   with	   diagnosis,	   and	   CCL25	   and	   CCL7	   were	   found	   to	   have	   the	   strongest	   effect	  
	  	  
(Table	  1).	  This	  indicates	  that	  a	  decrease	  in	  these	  six	  cytokines	  levels	  in	  OPMD	  is	  robust	  and	  
overcomes	  age	  and	  gender	  differences	  among	  patients.	  In	  mice,	  five	  cytokine	  genetics	  were	  
found	  to	  associate	  with	  expression	  level,	  but	  the	  direction	  of	  the	  effect	  was	  opposite	  to	  that	  
found	   in	   OPMD	   patients.	   Additionally,	   in	   mice,	   Ccl25,	   Il15,	   Lta	   and	   Ccl27	   were	   found	   to	  
associate	  with	  age	  (Table	  1).	  	  
From	  these	  six	  cytokines,	  IL15	  constitutive	  expression	  in	  muscles	  was	  previously	  shown,	  and	  
elevated	  IL15	  levels	  were	  found	  in	  conditions	  with	  increased	  muscle	  mass	  (30).	  Additionally,	  
reduced	   IL15	   levels	   were	   implicated	   in	   muscle	   wasting.	   Reduced	   Il15	   were	   found	   to	   be	  
causing	  muscle	  atrophy	  and	  muscle	  wasting	  in	  mice	  under	  stress	  conditions	  (31,	  32)	  and	  was	  
therefore	  proposed	  as	  a	  potential	  therapeutic	  target	  for	  muscle	  wasting	  (31).	  The	  expression	  
of	  CCL	  genes	   in	  muscles	  correlates	  with	  muscle wasting, for examples due to chronic binge 
alcohol or Adeno virus administration (33, 34).	  Network	  analysis	  of	  chemokine	  expression	  in	  
blood	   reveals	   consistent	   co-­‐expression	   in	   control,	   but	   it	   was	   gradually	   lost	   with	   cancer	  
disease	  progression	  (35).	  	  
	  
Several	  studies	  demonstrated	  that	  circulating	  cytokines	  levels	  change	  after	  muscle	  exercise	  
and	  in	  changing	  muscle	  physiology	  conditions	  (12-­‐14).	  It	  was	  suggested	  that	  oxidative	  stress	  
markers	  are	  secreted	  from	  muscles	  to	  blood	  after	  anaerobic	  exercise	  (36),	  and	  thus	  could	  be	  
used	  as	  measurers	   for	  muscle	  fatigue	   and	   pathology.	  Here	  we	  found	  that	   the	  expression	  
profile	  of	  six	  cytokines	  is	  specifically	  changed	  in	  affected	  OPMD	  muscles.	  We	  show	  that	  their	  
mRNA	   levels	   in	  muscles	   are	  associated	  with	   the	  disease.	   Future	   studies	   should	   investigate	  
levels	  of	   these	  cytokines	   in	  blood	  from	  OPMD.	  Additionally,	   future	  studies	  should	  examine	  
whether	   cytokine	   levels	   can	   predict	   disease	   severity	   and	   progression.	   Biomarkers	   are	  
employed	  to	  predict	  disease	  condition	  and	  to	  accurately	  report	  the	  efficacy	  of	  therapies (3).	  
For	  pre-­‐clinical	  assessment	  of	  therapies	  the	  same	  set	  of	  biomarkers	  should	  be	  employed	  in	  
patients	   and	   in	   animal	  models.	  Our	   results	   here	   reveal	   that	   the	   expression	   of	   the	  OPMD-­‐
dysregulated	  cytokines	  in	  humans	  affected	  by	  OPMD	  is	  opposite	  to	  that	  found	  in	  the	  mouse	  
model	  of	  OPMD.	  Moreover,	  we	  found	  that	  an	  age-­‐associated	  cytokine	  profile	  differ	  between	  
mouse	  and	  human.	  The	  basis	  of	  this	  distinct	  cytokine	  profile	  remains	  to	  be	  resolved,	  but	  may	  
relate	   to	   pathological	   differences	   in	   disease	   progression	   (atrophic	   stage,	   fibrosis,	  
inflammation,	   ect),	   or	   to	   differences	   between	   human	   VL	   and	   mouse	   TA	   muscles,	   or	   to	  
differences	   in	   muscle	   aging	   biology	   between	   the	   two	   organisms.	   This	   study	   reveals	  
molecular	   differences	   between	  OPMD	  muscles	   from	  heterozygous	   patients	   and	   the	   A17.1	  
mouse,	  and	  encourages	  the	  development	  of	  alternative	  models	  for	  OPMD,	  such	  as	  the	  one	  
	  	  
recently	   reported(37).	   Since	   subsets	   of	  muscles	   are	   predominantly	   affected	   in	   OPMD	   and	  
during	   aging(38),	   future	   studies	   should	   investigate	   the	   cluster	   of	   cytokines	   in	   different	  
muscles	  and	  correlate	  with	  circulating	  cytokine	  profiles.	  
In	  conclusion,	  we	   identified	  six	  cytokines	  whose	  mRNA	  expression	  profile	  altered	   in	  OPMD	  
muscles	   and	   is	   associated	   with	   OPMD	   symptoms.	   We	   found	   that	   changes	   in	   these	   six	  
cytokines	   are	   opposite	   to	   that	   found	   in	   a	   mouse	   model	   of	   OPMD,	   however	   their	   age-­‐
associated	   changes	   where	   similar.	   We	   show	   that	   expression	   of	   these	   genes	   form	   a	  
distinguished	  cluster	  in	  human.	  This	  cytokines	  cluster	  is	  significantly	  weakened	  in	  OPMD	  and	  
the	   expression	  of	   these	   genes	   can	  predict	   the	  disease.	  We	   suggest	   that	  mRNA	  expression	  
levels	  of	  these	  six	  cytokines	  can	  potentially	  be	  specific	  biomarkers	  for	  OPMD	  disease	  severity	  
and	  progression.	  
	  
	   	  
	  	  
Methods	  	  
OPMD	  patients,	  pre-­‐symptomatic	  carriers,	  controls	  and	  clinical	  features	  
Fifteen	   genetically	   confirmed	   OPMD	   patients	   and	   nine	   expPABPN1	   carriers	   at	   a	   pre-­‐
symptomatic	   stage	  were	   included	   in	   this	   study.	   Subjects’	   characteristics	   (age,	   gender	   and	  
diagnosis)	  are	  listed	  in	  Supplementary	  Table	  1.	  Age	  distribution	  between	  expPABPN1	  carriers	  
and	   controls	  did	  not	  differ	   (Supplementary	   Figure	  1).	  Cytokines	   levels	  were	  determined	   in	  
vastus	  lateralis,	  as	  in	  the	  Dutch	  and	  Danish	  patients	  Initial	  muscle	  symptoms	  also	  include	  the	  
limb	  griddle	  muscles	   (24,	  39,	  40).	   	  A	   subset	  of	   the	   subjects	   (control	  N=9;	  OPMD	  N=7)	  was	  
first	  analysed	  for	  15	  cytokines.	  Additional	  subjects	  (control	  N=7;	  OPMD	  N=8)	  were	  included	  
for	  analysis	  of	  a	  subset	  of	  7	  differentially	  expressed	  cytokines.	  Results	  are	  presented	  for	  the	  
combined	  data,	  and	  in	  models	  correction	  for	  possible	  technical	  variations	  between	  the	  two	  
groups	   (batch	  effect)	   is	   included	   in	  the	  multivariate	  models.	  The	  pre-­‐symptomatic	  subjects	  
were	   identified	  amongst	   the	  OPMD	  family	  members.	  Control	  biopsies	  were	  collected	   from	  
knee	   operations	   from	   subjects	   without	   OPMD.	   All	   subjects	   were	   described	   in	   previous	  
studies	  (24,	  26).	  Muscle	  biopsies	  collection	  and	  RNA	  isolation	  were	  carried	  out	  as	  described	  
in	   (26).	  The	  study	  was	  approved	  by	   the	   local	  Radboud,	  Nijmegen	  Ethical	  Committee	   (CMO	  
nr.	   2005/189)	   and	  written	   informed	   consent	   for	   RNA	   investigation	   was	   obtained	   from	   all	  
patients	  and	  controls.	  	  
cDNA	  synthesis	  and	  quantitative	  RT-­‐PCR	  	  
RNA	  samples	  from	  A17.1	  and	  FVB	  control	  at	  6	  and	  18	  weeks	  old	  animals	  were	  described	  in	  
(28).	   1	   µg	   total	   RNA	  was	   converted	   to	   cDNA	  using	   RevertAid	   RT	   Reverse	   Transcription	   Kit	  
(Thermo	  Fisher	  Scientific,	  MA	  USA).	  Quantitative	  RT-­‐PCR	  was	  performed	  using	  Syber-­‐Green	  
master	  mixture	  (Bio-­‐RAD	  Laboratories,	  USA)	  on	  LightCycler®	  480	  (Roche	  Diagnostics,	  Basel,	  
Switzerland).	   mRNA	   expression	   levels	   were	   determined	   after	   normalizing	   to	   HPRT	  
housekeeping	   gene	   using	   the	   dCT	   calculation;	   fold	   changes	   were	   calculated	   after	  
normalization	  to	  the	  average	  of	  control	  using	  the	  ddCT	  calculation.	  	  
Statistical	  analysis	  
Statistical	   significance	   of	   fold	   change	   was	   assessed	   in	   human	   samples	   with	   the	   non-­‐
parametric	  Mann-­‐Whitney	  t-­‐test.	  Analysis	  was	  carried	  out	  in	  Graphpad	  Prism	  6.	  	  
	  	  
Further	   analyses	   of	   data	   from	   the	  human	  OPMD	  patients	   and	   age-­‐matched	   controls	  were	  
carried	  out	  after	  transformation	  to	  the	  natural	  logarithm	  due	  to	  skewness	  of	  the	  expression	  
data.	   Multivariable	   linear	   regression	   models	   were	   used	   to	   assess	   age	   effects	   on	   the	  
expression	   levels	   (as	   a	   dependent	   variable).	   For	   the	   human	   samples,	   models	   included	  
diagnosis	   (0:	   control;	   1:	   OPMD),	   age,	   gender	   (0:	   female;	   1:male)	   and	   batch	   (1,	   2)	   as	  
independent	   variables.	   For	   the	   mouse	   samples	   (all	   are	   male	   and	   all	   isolations	   were	  
performed	   in	   one	   batch),	   included	   genetics	   (0:	   FVB;	   1:	   A17.1)	   and	   age	   (0:	   6	  weeks;	   1:	   18	  
weeks).	  Pearson	  correlation	  tests	  were	  employed	  to	  assess	  correlations	  in	  expression	  levels	  
between	   genes.	   Statistical	   analyses	   were	   performed	  with	   IBM	   SPSS	   Statistics	   (version	   20)	  
and.	  P-­‐values	  <0.05	  were	  considered	  as	  statistically	   significant.	  Correlation	  heatmaps	  were	  
generated	   in	   RStudio	   (version	   0.99.484)	   using	   the	   ‘corrgram’	   package	   (version	   1.8)	   with	  
Pearson	   correlations.	   Genes	   were	   ordered	   with	   PCA-­‐based	   re-­‐ordering	   on	   the	   control	  
condition.	  All	  other	  charts	  were	  generated	  in	  Graphpad	  Prism	  6.	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Table	  1:	  Age-­‐association	  of	  differentially	  expressed	  cytokines	  in	  human	  and	  mouse.	  
	  	   Human	   Mouse	  
	  	   Diagnosis	   Age	   Genetics	   Age	  
	  	   B	  (SE)	   p-­‐value	   B	  (SE)	   p-­‐value	   B	  (SE)	   p-­‐value	   B	  (SE)	   p-­‐value	  
CCL25	   -­‐1.62	  (0.39)	   <	  0.0001	   -­‐0.02	  (0.02)	   0.392	   	  0.73	  (0.15)	   <	  0.0001	   -­‐	  0.48	  (0.15)	   0.004	  
CCL7	   -­‐1.71	  (0.53)	   0.004	   -­‐0.03	  (0.03)	   0.217	   	  0.55	  (0.24)	   0.038	   0.09	  (0.24)	   0.723	  
IL15	   -­‐0.40	  (0.17)	   0.028	   0.001	  (0.01)	   0.926	   0.96	  (0.10)	   <	  0.0001	   0.58	  (0.1)	   <	  0.0001	  
LTA	   -­‐0.64	  (0.29)	   0.035	   0.02	  (0.01)	   0.116	   1.14	  (0.17)	   <	  0.0001	   -­‐	  0.57	  (0.17)	   0.003	  
CCL8	   -­‐0.75	  (0.34)	   0.035	   -­‐0.004	  (0.02)	   0.796	   0.74	  (0.38)	   0.067	   -­‐	  0.92	  (0.38)	   0.026	  
CCL27	   -­‐0.41	  (0.19)	   0.047	   -­‐0.01	  (0.01)	   0.253	   0.49	  (0.13)	   0.001	   -­‐	  0.45	  (0.13)	   0.002	  
Betas	   (B)	   and	   standard	   errors	   (SE)	   of	   effects	   of	   diagnosis	   and	   age	   on	   cytokine	   expression	  
levels	   are	   provided.	   Multivariable	   linear	   regression	   models	   were	   employed.	   For	   human	  
samples	  models	  included	  diagnosis	  (0:	  controls,	  1:	  OPMD),	  age	  (in	  years),	  gender	  (0:	  female,	  
1:	  male)	  and	  PCR	  experiment	  as	  independent	  variables.	  For	  mouse	  samples	  models	  included	  
genetics	   (0:	  FVB,	  1:	  A17.1)	  and	  age	   (0:	  6	  weeks,	  1:	  18	  weeks)	  as	   independent	  variables.	  P-­‐




Fig.1:	   Differential	   expression	   of	   cytokines	   in	   OPMD	   patients	   and	   controls	   and	   mouse	  
model	  
Plots	  show	  mRNA	  fold	  change	  in	  human	  (A-­‐B)	  or	  mouse	  (C-­‐D)	  muscles.	  A.	  expression	  levels	  in	  
OPMD	  (N=15)	  vs.	  age-­‐matched	  controls	  (N=16,	  average	  age	  59.1	  and	  56.1,	  respectively).	  B.	  
Pre-­‐symptomatic	   (pre-­‐symp)	   (N=10),	   vs.	   age-­‐matched	  controls	   (N=9	   (average	  age	  37.9	  and	  
36.7,	   respectively)	  C-­‐D	  Expression	   levels	   in	  mouse	  A17.1	  vs.	   FVB	  control	   at	  6	   (C)	  or	  18	   (D)	  
weeks	   of	   age.	  N=6	   for	   each	   group.	   	   P-­‐values	   for	   human	   samples	  were	   determined	  with	   a	  
non-­‐parametric	  Mann-­‐Whitney	  t-­‐test.	  Significant	  changes	  are	  depicted	  in	  bold.	  	  	  
	  	  
	  
Fig.2:	  	  	  Co-­‐expression	  clustering	  of	  differentially	  expressed	  genes	  in	  control	  and	  OPMD.	  
Correlation	  heatmaps	  of	  Pearson	  correlations	  show	  correlations	  between	  expression	   levels	  
show	  patterns	  of	  gene	  clustering	   in	  human	   (A-­‐B)	  or	  mouse	   (C).	   In	   (A)	  15	  cytokines	   related	  
genes	   were	   included	   in	   the	   analysis,	   and	   in	   (B)	   and	   (C)	   only	   the	   OPMD	   dysregulated	  
cytokines	   are	   included.	   Dataset	   in	   (A):	   control	   N=10,	   OPMD	   N=9;	   dataset	   in	   (B):	   control	  
N=16;	   OPMD	   N=15.	   Positive	   Pearson	   correlation	   values	   are	   depicted	   in	   blue	   and	   in	   red	  
negative	   values,	   according	   to	   the	   values	   scale.	   Genes	   are	   ordered	   using	   a	   PCA-­‐based	   re-­‐
ordering	   in	   the	   control	   conditions.	   Significant	   correlations	   are	   depicted	   with	   filled	   boxes,	  
while	   non-­‐significant	   correlations	   are	   striped.	   The	   Pearson	   correlation	   values	   are	   found	   in	  
Supplementary	  Table	  3.	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Supplementry	  Figure	  1:	  Age-­‐distribution	  of	  subjects	  in	  this	  study.	  
NA=not	  aviable.	  The	  age	  of	  presymptomatic	  carriers	  is	  not	  attributed,	  and	  therefore	  
only	  the	  age-­‐range	  is	  indicated.	  
	  
Controls	   expPABPN1	  carriers	  



























NA	   F	  
35	   F	   NA	   M	  
35	   F	   NA	   F	  
36	   F	   NA	   F	  
38	   F	   NA	   M	  
39	   M	   NA	   F	  
39	   M	   NA	   F	  
40	   M	   NA	   F	  
41	   M	   NA	   F	  
42	   M	   	  	   	  	  


























45	   F	  
43	   M	   47	   F	  
45	   F	   47	   F	  
52	   F	   49	   F	  
53	   M	   51	   F	  
54	   F	   54	   F	  
58	   F	   54	   F	  
60	   F	   55	   F	  
60	   M	   57	   F	  
67	   F	   57	   M	  
67	   F	   60	   F	  
67	   F	   60	   F	  
68	   M	   63	   F	  
70	   F	   68	   F	  
73	   M	   74	   M	  
77	   M	   	  	   	  	  
	  
	  
Scatter	  plot	  shows	  the	  distribution	  of	  subject	  across	  age	  in	  controls	  (gray)	  and	  
expPABPN1	  carriers	  (red).	  Significant	  age-­‐distribution	  between	  the	  two	  groups	  was	  
not	  found.	  
	  
Supplementry	  to	  Figure	  1:	  Expression	  levels	  of	  15	  cytokine	  related	  genes	  in	  control	  
and	  OPMD	  muscles.	  
	  
	  
Expression	  levels	  are	  calculated	  by	  the	  dCT	  after	  normalization	  to	  HPRT	  levels.	  HPRT	  
levels	  were	  consistent	  across	  samples.	  Control	  N=10;	  OPMD	  N=9.	  Significant	  change	  
was	  assessed	  with	  unpaired	  nonparametric	  T-­‐test.	  	  
	  
Supplementry	  Table	  2:	  Age	  or	  diagnosis	  association	  in	  human	  and	  mouse.	  	  
	  
Human	   Mouse	  
	  
Control	   OPMD	   FVB	   A17.1	  
	  
B	  (SE)	   pvalue	   B	  (SE)	   pvalue	   B	  (SE)	   pvalue	   B	  (SE)	   pvalue	  
IL15	   0.02	  (0.01)	   0.123	   -­‐	  0.03	  (0.01)	   0.087	   -­‐	  0.60	  (0.08)	   <0.001	   -­‐	  0.56	  (0.20)	   0.02	  
LTA	   0.02	  (0.01)	   0.147	   -­‐	  0.13	  (0.03)	   0.677	   -­‐	  0.43	  (0.12)	   0.006	   -­‐	  0.70	  (0.32)	   0.05	  
CCL25	   -­‐	  0.03	  (0.02)	   0.140	   0.00	  (0.04)	   0.961	   -­‐	  0.11	  (0.09)	   0.22	   -­‐	  0.84	  (0.24)	   0.006	  
CCL27	   -­‐	  0.01	  (0.01)	   0.786	   -­‐	  0.02	  (0.15)	   0.184	   -­‐	  0.20	  (0.11)	   0.100	   -­‐	  0.70	  (0.21)	   0.007	  
CCL7	   -­‐	  0.04	  (0.02)	   0.131	   -­‐	  0.02	  (0.06)	   0.764	   -­‐	  0.14	  (0.18)	   0.43	   0.32	  (0.45)	   0.50	  










































* * * *
*
Multivariable	   linear	   regression	   models	   on	   ln-­‐transformed	   expression	   levels	   stratified	   for	  
diagnosis	   (human)	   or	   genetics	   (mouse)	  were	  used	   to	   assess	   age	   effects	   on	   the	   expression	  
levels	  (as	  a	  dependent	  variable).	  Independent	  variables	  in	  the	  human	  dataset	  included	  age,	  
gender	   (0:	   female;	   1:male)	   and	   batch	   (1,	   2).	   Independent	   variables	   in	   the	  mouse	   dataset	  
included	  age.	  Betas	  for	  age	  (standard	  errors)	  are	  provided.	  Models	   for	  the	  human	  samples	  
are	  adjusted	  for	  possible	  gender	  and	  batch	  effects.	  In	  human	  OPMD	  and	  age-­‐matched	  group	  
are	   included	   (Supplementary	   Table	   1,	   age	   is	   a	   contentious	   variable.	   In	   mouse,	   age	   is	   an	  
ordinal	  covariate	  (0=6	  weeks;	  1=18	  weeks).  	  
	  
	  
Supplementry	  Table	  3:	  Pearson	  correlations	  in	  controls	  and	  OPMD.	  
A.	  Correlations	  in	  human	  control	  and	  OPMD	  amongst	  15	  cytokines-­‐related	  genes.	  
Figures/pearson	  correlation.xlsx	  
B.	  Correlations	  amongst	  the	  six	  OPMD-­‐significant	  cytokines	  in	  human.	  
Figures/pearson	  correlation.xlsx	  	  
C.	  Correlations	  amongst	  the	  six	  OPMD-­‐significant	  cytokines	  in	  mouse.	  
Figures/pearson	  correlation.xlsx	  
	  
	  
	  
	  	  
